| Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study O Lortholary, MO Chandesris, CB Livideanu, C Paul, G Guillet, E Jassem, ... The Lancet 389 (10069), 612-620, 2017 | 120 | 2017 |
| In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells E Soucie, K Hanssens, T Mercher, S Georgin-Lavialle, G Damaj, ... Blood, The Journal of the American Society of Hematology 120 (24), 4846-4849, 2012 | 112 | 2012 |
| Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients S Lourari, C Herve, V Doffoel‐Hantz, N Meyer, C Bulai‐Livideanu, ... Journal of the European Academy of Dermatology and Venereology 25 (10), 1238 …, 2011 | 86 | 2011 |
| ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases G Damaj, M Joris, O Chandesris, K Hanssens, E Soucie, D Canioni, ... PloS one 9 (1), e85362, 2014 | 85 | 2014 |
| Calculation of cut‐off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for … C Boulard, S Duvert Lehembre, C Picard‐Dahan, JS Kern, G Zambruno, ... British Journal of Dermatology 175 (1), 142-149, 2016 | 73 | 2016 |
| GENIPSO: a French prospective study assessing instantaneous prevalence, clinical features and impact on quality of life of genital psoriasis among patients consulting for psoriasis M Larsabal, S Ly, E Sbidian, M Moyal‐Barracco, JN Dauendorffer, ... British Journal of Dermatology 180 (3), 647-656, 2019 | 65 | 2019 |
| Large international validation of ABSIS and PDAI pemphigus severity scores V Hebert, C Boulard, E Houivet, SD Lehembre, L Borradori, R Della Torre, ... Journal of investigative dermatology 139 (1), 31-37, 2019 | 62 | 2019 |
| Omalizumab in the treatment of adult patients with mastocytosis: a systematic review F Jendoubi, N Gaudenzio, A Gallini, M Negretto, C Paul, ... Clinical & Experimental Allergy 50 (6), 654-661, 2020 | 59 | 2020 |
| Early relapse of psoriasis after stopping brodalumab: a retrospective cohort study in 77 patients M Masson Regnault, MP Konstantinou, A Khemis, Y Poulin, M Bourcier, ... Journal of the European Academy of Dermatology and Venereology 31 (9), 1491-1496, 2017 | 54 | 2017 |
| Omalizumab therapy for mast cell-mediator symptoms in patients with ISM, CM, MMAS, and MCAS R Lemal, G Fouquet, L Terriou, M Vaes, CB Livideanu, L Frenzel, ... The Journal of Allergy and Clinical Immunology: In Practice 7 (7), 2387-2395. e3, 2019 | 51 | 2019 |
| Cellular phone addiction and allergic contact dermatitis to nickel. C Livideanu, F Giordano-Labadie, C Paul Contact Dermatitis (01051873) 57 (2), 2007 | 49 | 2007 |
| Telangiectasia macularis eruptiva perstans (TMEP): a form of cutaneous mastocytosis with potential systemic involvement M Severino, MO Chandesris, S Barete, E Tournier, B Sans, C Laurent, ... Journal of the American Academy of Dermatology 74 (5), 885-891. e1, 2016 | 46 | 2016 |
| VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy M Magnol, L Couvaras, Y Degboé, E Delabesse, C Bulai-Livideanu, ... Rheumatology 60 (9), e314-e315, 2021 | 42 | 2021 |
| Efficacy, safety and tolerability of an optimized avulsion technique with onyster®(40% urea ointment with plastic dressing) ointment compared to bifonazole-urea ointment for … M Lahfa, C Bulai-Livideanu, R Baran, JP Ortonne, B Richert, A Tosti, ... Dermatology 226 (1), 5-12, 2013 | 42 | 2013 |
| Prevalence and prognostic value of cutaneous manifestations in patients with myelodysplastic syndrome C Farah, C Bulai Livideanu, J Jegu, C Paul, R Viraben, L Lamant, ... Journal of the European Academy of Dermatology and Venereology 24 (10), 1171 …, 2010 | 42 | 2010 |
| Treatment of port wine stains with pulsed dye laser and topical timolol: a multicenter randomized controlled trial T Passeron, A Maza, E Fontas, G Toubel, P Vabres, C Livideanu, ... British Journal of Dermatology 170 (6), 1350-1353, 2014 | 40 | 2014 |
| Efficacy of ustekinumab in palmoplantar psoriasis C Bulai Livideanu, M Lahfa, J Mazereeuw-Hautier, C Paul Dermatology 221 (4), 321-323, 2010 | 40 | 2010 |
| Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital … A Maza, MA Richard, F Aubin, JP Ortonne, S Prey, H Bachelez, ... British Journal of Dermatology 167 (3), 643-648, 2012 | 38 | 2012 |
| Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients M Best, M Jachiet, N Molinari, F Manna, C Girard, V Pallure, A Cosnes, ... Journal of the European Academy of Dermatology and Venereology 32 (7), 1164-1172, 2018 | 36 | 2018 |
| Prevalence and risk factors for fragility fracture in systemic mastocytosis Y Degboé, M Eischen, D Nigon, PA Apoil, C Mailhol, E Tournier, ... Bone 105, 219-225, 2017 | 34 | 2017 |
